Effect of amylin on memory and central insulin resistance in a rat model of Alzheimer’s disease

References

• Adler, B.L., et al., 2014. Neuroprotective effects of the amylin analogue Pramlintide on Alzheimer's disease pathogenesis and cognition. Neurobiology of aging, 35 (4), 793–801.
   PubMed Web of Science ®Google Scholar
• Alzoubi, H., et al., 2014. Metformin eased cognitive impairment induced by chronic l-methionine administration: potential role of oxidative stress. Current neuropharmacology, 12 (2), 186–192.
   PubMed Web of Science ®Google Scholar
• Banks, W.A. and Kastin, A.J., 1998. Differential permeability of the blood–brain barrier to two pancreatic peptides: insulin and amylin. Peptides, 19 (5), 883–889.
   PubMed Web of Science ®Google Scholar
• Berhanu, W.M., Yaşar, F., and Hansmann, U.H.E., 2013. In silico cross seeding of Aβ and amylin fibril-like oligomers. ACS chemical neuroscience, 4 (11), 1488–1500.
   PubMed Web of Science ®Google Scholar
• Bevins, R.A. and Besheer, J., 2006. Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study recognition memory. Nature protocols, 1 (3), 1306–1311.
   PubMed Web of Science ®Google Scholar
• Brands, A.M., et al., 2005. The effects of type 1 diabetes on cognitive performance: a meta-analysis. Diabetes care, 28 (3), 726–735.
   PubMed Web of Science ®Google Scholar
• Cai, T., et al., 2016. Effect of metformin on cognitive dysfunction in animal with insulin resistance: a non-quantitative systematic review of randomized controlled trials. International journal of clinical and experimental medicine, 9, 3988–3994.
   Web of Science ®Google Scholar
• Chapman, C.D., et al., 2017. Intranasal insulin in Alzheimer's disease: food for thought. Neuropharmacology, 136, 196–201.
   PubMed Web of Science ®Google Scholar
• Chen, Y., et al., 2014. Intracerebroventricular streptozotocin exacerbates Alzheimer-like changes of 3xTg-AD mice. Molecular neurobiology, 49 (1), 547–562.
   PubMed Web of Science ®Google Scholar
• Craft, S., 2006. Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications. Alzheimer disease and associated disorders, 20 (4), 298–301.
   PubMed Web of Science ®Google Scholar
• Craft, S., et al., 2003. Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer’s disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology, 28 (6), 809–822.
   PubMed Web of Science ®Google Scholar
• Craft, S., Zallen, G., and Baker, L.D., 1992. Glucose and memory in mild senile dementia of the Alzheimer type. Journal of clinical and experimental neuropsychology, 14 (2), 253–267.
   PubMed Web of Science ®Google Scholar
• De La Monte, S.M., et al., 2006. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. Journal of Alzheimer's disease: JAD, 10 (1), 89–109.
   PubMed Web of Science ®Google Scholar
• Edvinsson, L., Goadsby, P.J., and Uddman, R., 2001. Amylin: localization, effects on cerebral arteries and on local cerebral blood flow in the cat. The scientific world journal, 1, 168–180.
   Google Scholar
• Ferrer, I., et al., 2005. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Current Alzheimer research, 2 (1), 3–18.
   PubMedGoogle Scholar
• Fukuda, T., et al., 2013. Electrophysiologically identified presynaptic mechanisms underlying amylinergic modulation of area postrema neuronal excitability in rat brain slices. Brain research, 1494, 9–16.
   PubMed Web of Science ®Google Scholar
• Gingell, J.J., Burns, E.R., and Hay, D.L., 2014. Activity of Pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors. Endocrinology, 155 (1), 21–26.
   PubMed Web of Science ®Google Scholar
• Gitter, B.D., et al., 2000. Human amylin stimulates inflammatory cytokine secretion from human glioma cells. Neuroimmunomodulation, 7 (3), 147–152.
   PubMed Web of Science ®Google Scholar
• Gupta, A., Bisht, B., and Dey, C.S., 2011. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer’s-like changes. Neuropharmacology, 60 (6), 910–920.
   PubMed Web of Science ®Google Scholar
• Hoogwerf, B.J., Doshi, K.B., and Diab, D., 2008. Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk. Vascular health and risk management, 4, 355–362.
   PubMedGoogle Scholar
• Hooper, C., Killick, R., and Lovestone, S., 2008. The GSK3 hypothesis of Alzheimer's disease. Journal of neurochemistry, 104 (6), 1433–1439.
   PubMed Web of Science ®Google Scholar
• Hoyer, S. and Nitsch, R., 1989. Cerebral excess release of neurotransmitter amino acids subsequent to reduced cerebral glucose metabolism in early-onset dementia of Alzheimer type. Journal of neural transmission, 75 (3), 227–232.
   PubMed Web of Science ®Google Scholar
• Hoyer, S., Nitsch, R., and Oesterreich, K., 1991. Predominant abnormality in cerebral glucose utilization in late-onset dementia of the Alzheimer type: a cross-sectional comparison against advanced late-onset and incipient early-onset cases. Journal of neural transmission – Parkinson's disease and dementia section, 3 (1), 1–14.
   Google Scholar
• Imfeld, P., et al., 2012. Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population‐based case–control study. Journal of the American geriatrics society, 60 (5), 916–921.
   PubMed Web of Science ®Google Scholar
• Jackson, K., et al., 2013. Amylin deposition in the brain: a second amyloid in Alzheimer disease? Annals of neurology, 74 (4), 517–526.
   PubMed Web of Science ®Google Scholar
• Jhamandas, J.H., et al., 2011. Actions of β-amyloid protein on human neurons are expressed through the amylin receptor. The American journal of pathology, 178 (1), 140–149.
   PubMed Web of Science ®Google Scholar
• Lannert, H. and Hoyer, S., 1998. Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behavioral neuroscience, 112 (5), 1199–1208.
   PubMed Web of Science ®Google Scholar
• Li, J., et al., 2012. Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice. Pharmacology biochemistry and behavior, 101 (4), 564–574.
   PubMed Web of Science ®Google Scholar
• Lim, Y.-A., et al., 2008. Human but not rat amylin shares neurotoxic properties with Abeta42 in long-term hippocampal and cortical cultures. FEBS letters, 582 (15), 2188–2194.
   PubMed Web of Science ®Google Scholar
• McNay, E.C. and Recknagel, A.K., 2011. Reprint of: ‘Brain insulin signaling: a key component of cognitive processes and a potential basis for cognitive impairment in type 2 diabetes’. Neurobiology of learning and memory, 96 (4), 517–528.
   PubMed Web of Science ®Google Scholar
• Mehan, S., et al., 2011. Effect of mitogen activated protein kinase inhibitor in animal model of Alzheimer’s diseases. International journal of pharm prof research, 2, 212–223.
   Google Scholar
• Mitsukawa, T., et al., 1990. Islet amyloid polypeptide response to glucose, insulin, and somatostatin analogue administration. Diabetes, 39 (5), 639–642.
   PubMed Web of Science ®Google Scholar
• Moon, H.-S., et al., 2011. Leptin and amylin act in an additive manner to activate overlapping signaling pathways in peripheral tissues: in vitro and ex vivo studies in humans. Diabetes care, 34 (1), 132–138.
   PubMed Web of Science ®Google Scholar
• Moore, E., et al., 2012. Cognitive impairment and vitamin B12: a review. International psychogeriatrics, 24 (04), 541–556.
   PubMedGoogle Scholar
• Moore, E.M., et al., 2013. Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes care, 36 (10), 2981–2987.
   PubMed Web of Science ®Google Scholar
• Morris, R., et al., 1982. Place navigation impaired in rats with hippocampal lesions. Nature, 297 (5868), 681–683.
   PubMed Web of Science ®Google Scholar
• Nguyen, T.T.L., et al., 2018. A review of brain insulin signaling in mood disorders: from biomarker to clinical target. Neuroscience & biobehavioral reviews, 92, 7–15.
   PubMed Web of Science ®Google Scholar
• Nikoulina, S.E., et al., 2002. Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. Diabetes, 51 (7), 2190–2198.
   PubMed Web of Science ®Google Scholar
• Nitsch, R. and Hoyer, S., 1991. Local action of the diabetogenic drug, streptozotocin, on glucose and energy metabolism in rat brain cortex. Neuroscience letters, 128 (2), 199–202.
   PubMed Web of Science ®Google Scholar
• Nonoyama, A., et al., 2008. A biophysical characterization of the peptide drug Pramlintide (AC137) using empirical phase diagrams. Journal of pharmaceutical sciences, 97 (7), 2552–2567.
   PubMed Web of Science ®Google Scholar
• Oliveira, W.H., et al., 2016. Effects of metformin on inflammation and short-term memory in streptozotocin-induced diabetic mice. Brain research, 1644, 149–160.
   PubMed Web of Science ®Google Scholar
• Ott, A., et al., 1999. Diabetes mellitus and the risk of dementia: the Rotterdam study. Neurology, 53 (9), 1937–1942.
   PubMed Web of Science ®Google Scholar
• Potes, C.S., et al., 2012. Involvement of the extracellular signal-regulated kinase 1/2 signaling pathway in amylin's eating inhibitory effect. American journal of physiology-regulatory, integrative and comparative physiology, 302 (3), R340–R351.
   PubMed Web of Science ®Google Scholar
• Pourmotabbed, A., et al., 2011. Effect of prenatal pentylenetetrazol-induced kindling on learning and memory of male offspring. Neuroscience, 172, 205–211.
   PubMed Web of Science ®Google Scholar
• Qiu, W.Q., et al., 2014. Positive association between plasma amylin and cognition in a homebound elderly population. Journal of Alzheimer's disease, 42 (2), 555–563.
   PubMed Web of Science ®Google Scholar
• Reger, M., et al., 2008. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology, 70 (6), 440–448.
   PubMed Web of Science ®Google Scholar
• Reifert, J., Hartung-Cranston, D., and Feinstein, S.C., 2011. Amyloid β-mediated cell death of cultured hippocampal neurons reveals extensive tau fragmentation without increased full-length tau phosphorylation. Journal of biological chemistry, 286 (23), 20797–20811.
   PubMed Web of Science ®Google Scholar
• Roth, J.D., 2013. Amylin and the regulation of appetite and adiposity: recent advances in receptor signaling, neurobiology and pharmacology. Current opinion in endocrinology, diabetes and obesity, 20 (1), 8–13.
   PubMed Web of Science ®Google Scholar
• Schafe, G.E., et al., 2000. Activation of ERK/MAP kinase in the amygdala is required for memory consolidation of pavlovian fear conditioning. The journal of neuroscience, 20 (21), 8177–8187.
   PubMed Web of Science ®Google Scholar
• Selkoe, D.J., 1998. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends in cell biology, 8 (11), 447–453.
   PubMed Web of Science ®Google Scholar
• Sharma, A.K., et al., 2006. Development of a percutaneous cerebrospinal fluid collection technique in F-344 rats and evaluation of cell counts and total protein concentrations. Toxicologic pathology, 34 (4), 393–395.
   PubMed Web of Science ®Google Scholar
• Shen, Y., et al., 2006. Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Nature, 443 (7113), 870–874.
   PubMed Web of Science ®Google Scholar
• Takashima, A., et al., 1998. Presenilin 1 associates with glycogen synthase kinase-3β and its substrate tau. Proceedings of the national academy of sciences, 95 (16), 9637–9641.
   PubMed Web of Science ®Google Scholar
• Takasu, N., et al., 1991. Streptozocin- and alloxan-induced H2O2 generation and DNA fragmentation in pancreatic islets. H2O2 as mediator for DNA fragmentation. Diabetes, 40 (9), 1141–1145.
   PubMed Web of Science ®Google Scholar
• Tarasoff-Conway, J.M., et al., 2015. Clearance systems in the brain—implications for Alzheimer disease. Nature reviews neurology, 11 (8), 457–470.
   PubMed Web of Science ®Google Scholar
• Terry, A.V., Jr, 2000. Spatial navigational (water maze) tasks. In: Methods of behavior analysis in neuroscience. CRC Press, 169–182.
   Google Scholar
• Trevaskis, J.L., et al., 2010. Enhanced amylin-mediated body weight loss in estradiol-deficient diet-induced obese rats. Endocrinology, 151 (12), 5657–5668.
   PubMed Web of Science ®Google Scholar
• Tucker, H.M., et al., 2002. Human amylin induces “apoptotic” pattern of gene expression concomitant with cortical neuronal apoptosis. Journal of neurochemistry, 71 (2), 506–516.
   Google Scholar
• Turk, J., et al., 1993. Biochemical evidence for nitric oxide formation from streptozotocin in isolated pancreatic islets. Biochemical and biophysical research communications, 197 (3), 1458–1464.
   PubMed Web of Science ®Google Scholar
• Vieira, M.N., Lima-Filho, R.A., and De Felice, F.G., 2017. Connecting Alzheimer's disease to diabetes: underlying mechanisms and potential therapeutic targets. Neuropharmacology, 136 (Pt B), 160–171.
   PubMedGoogle Scholar
• Wang, E., et al., 2017. Amylin treatment reduces neuroinflammation and ameliorates abnormal patterns of gene expression in the cerebral cortex of an Alzheimer’s disease mouse model. Journal of Alzheimer's disease, 56 (1), 47–61.
   PubMed Web of Science ®Google Scholar
• Wang, J., et al., 2012. Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation. Cell stem cell, 11 (1), 23–35.
   PubMed Web of Science ®Google Scholar
• Zapecka-Dubno, B., et al., 2011. Effect of oral antidiabetic agents on plasma amylin level in patients with non-insulin-dependent diabetes mellitus (type 2). Arzneimittelforschung, 49 (04), 330–334.
   Google Scholar
• Zhu, H., et al., 2015. Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer’s disease. Molecular psychiatry, 20 (2), 252–262.
   PubMed Web of Science ®Google Scholar
• Zhu, H., et al., 2017. Amylin receptor ligands reduce the pathological cascade of Alzheimer's disease. Neuropharmacology, 119, 170–181.
   PubMed Web of Science ®Google Scholar